Revolution Medicines reported standout Phase III data for its once-daily oral daraxonrasib in metastatic pancreatic ductal adenocarcinoma, with investors reacting strongly to the early readout. In the intent-to-treat population, the company cited median overall survival of 13.2 months versus 6.7 months for standard-of-care chemotherapy, along with a hazard ratio of 0.40. The coverage also details the stock response following the announcement, including a sharp weekly surge and continued gains as analysts weighed the odds of a clear efficacy win. Jefferies’ Faisal Khurshid pointed to expectations set from statistical simulations, characterizing the disclosed performance as exceeding those benchmarks. Revolution said it is moving with urgency toward global regulatory submissions as it advances the therapy across RAS-addicted cancers beyond pancreatic cancer.